In the Lab Angus Chen STAT Plus: Engineered virus shows promise against aggressive form of breast cancer
Biotech Jason Mast STAT Plus: Legend says its CAR-T outperformed conventional therapy for multiple myeloma
Special Report Rosa Furneaux and Laura Margottini — TBIJ STAT Plus: The drug was meant to save children’s lives. Instead, they’re dying
Politics Jonathan Wosen STAT Plus: Liquid-biopsy firm Grail is spending more than ever lobbying Congress
Health Tech Casey Ross STAT Plus: As more never-smokers develop lung cancer, researchers test an AI model to predict patient risk
Biotech Allison DeAngelis STAT Plus: How one private biotech seized on JPM to emerge from stealth and tell its story
On Target Angus Chen STAT Plus: Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
On Target Angus Chen STAT Plus: In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6
Biotech Jason Mast STAT Plus: After four years of big talk, mega startup Sana prepares to deliver some data
Biotech Jonathan Wosen STAT Plus: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo
Biotech Jonathan Wosen STAT Plus: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
Biotech Jonathan Wosen STAT Plus: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine
Pharmalot Ed Silverman Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Exclusive Jason Mast STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Biotech Jason Mast STAT Plus: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success
Health Angus Chen STAT Plus: Parker Institute extends ‘crazy idea’ funding to two more cancer centers
Biotech Adam Feuerstein STAT Plus: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study
Biotech Jonathan Wosen STAT Plus: Guardant Health trial of colon cancer liquid biopsy test disappoints observers
In the Lab Jonathan Wosen Study offers a genetic explanation for why some drugs trigger a deadly brain disease
Health Angus Chen STAT Plus: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia
Biotech Adam Feuerstein STAT Plus: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed
Biotech Adam Feuerstein STAT Plus: Affimed’s natural killer cell therapy has murky path forward despite encouraging results